This webinar discusses the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

The goal of precision oncology is to identify and target molecular events that give rise to tumor growth and progression. Although the overall success of this approach for all tumor types is debated, it is clear that in some instances this approach has yielded dramatic results. The mutation spectrum of cancers encompasses driver missense and indel mutations, copy number abnormalities and coding fusions, many of which are still routinely analyzed with independent molecular pathology and cytogenetic assays. Moving forward, it is clear that if we are to improve the outcomes of the majority of patients with recalcitrant tumors, we need to update the histological diagnostic standards to incorporate molecular markers to propose more rational approaches to combined therapies. 

This webinar focuses on the use of a hybrid capture-based FFPE DNA sequencing methodology to move toward this goal. Research into the technical feasibility, cost-effectiveness, and bioinformatics analysis workflows are described.